Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Covance’s Shanghai, China Facility Receives SFDA GLP Certification

Published: Wednesday, December 05, 2012
Last Updated: Wednesday, December 05, 2012
Bookmark and Share
SFDA certification validates Covance's consistent global quality.

Covance Inc. has announced that its early development facility located in Shanghai, China, has received a Good Laboratory Practice (GLP) Certificate from the State Food and Drug Administration (SFDA) of the People's Republic of China.

The Covance facility in Shanghai provides nonclinical safety assessment, bioanalytical, in vivo pharmacology, and DMPK services.

Since opening its early development facility in Shanghai in August 2010, Covance has secured several key accreditations from international regulatory bodies.

In February 2011 the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) awarded full accreditation to the company's early development research facility.

The company also received GLP certification from the Belgian GLP Monitoring Authority, a member of the Organization for Economic Cooperation and Development (OECD), in September 2011.

The most recent accreditation from the SFDA demonstrates that Covance continues to invest in China to offer its clients a full range of expert nonclinical and chemistry services.

"Covance is now the only global CRO with SFDA GLP certification in China. Our early development facility in Shanghai offers world-class quality and expertise to companies with testing needs in China and the Asia Pacific region. Partnering with Covance in China will provide the gateway for local and regional pharmaceutical companies to access global markets and help save clients' time and costs in their drug development process," said Honggang Bi, Corporate Vice President and General Manager, Covance China.

"Covance's early development facilities offer a comprehensive range of nonclinical drug development services to clients around the globe, helping them make fast and effective drug development decisions to progress their most promising product candidates. In addition to our early development facility in Shanghai, we also offer clinical and central laboratory services to clients across Asia, making Covance the only CRO with the expertise to develop a molecule from discovery through all preclinical and clinical milestones. We believe this makes Covance a 'one stop shop' for companies wishing to develop drug candidates in Asia and across the globe," added Steve Street, Global Vice President and General Manager, overseeing Covance's worldwide safety assessment and pharmaceutical chemistry services.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Covance to Open Second cGMP Pharmacy in U.S.
Covance is the only CRO to offer cGMP manufacturing in a U.S. Phase I clinical research unit.
Saturday, October 03, 2015
Covance and Frenova Renal Collaboration
Researchers will share and analyze data to improve lives of patients living with chronic kidney disease and end stage renal disease.
Wednesday, September 24, 2014
Covance Acquires Medaxial
Expanding global market access, reimbursement, and communications solutions.
Friday, May 23, 2014
PathoQuest and Covance to Offer NGS-based Biosafety Assessments
Unique technology for virus screening in a single comprehensive assay to overcome the current limitations with predefined sets of known viruses.
Thursday, November 07, 2013
Covance and M2Gen® Enter into Alliance
Combines Covance’s comprehensive drug development capabilities with M2Gen’s innovative cancer-focused data warehouse to help accelerate development of targeted therapies for cancer patients.
Friday, March 01, 2013
Scientific News
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos